Clinical trial NCT02074631 - References

Osteoporosis — Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation

Citation(s)

•   Astrom E, Soderhall S
  Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002 May;86(5):356-64. doi: 10.1136/adc.86.5.356.
•   Baxter-Jones AD, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA
  Bone mineral accrual from 8 to 30 years of age: an estimation of peak bone mass. J Bone Miner Res. 2011 Aug;26(8):1729-39. doi: 10.1002/jbmr.412.
•   Bhatia S, Ramsay NK, Weisdorf D, Griffiths H, Robison LL
  Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies. Bone Marrow Transplant. 1998 Jul;22(1):87-90. doi: 10.1038/sj.bmt.1701275.
•   Brumsen C, Hamdy NA, Papapoulos SE
  Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore). 1997 Jul;76(4):266-83. doi: 10.1097/00005792-199707000-00005.
•   Buison AM, Kawchak DA, Schall JI, Ohene-Frempong K, Stallings VA, Leonard MB, Zemel BS
  Bone area and bone mineral content deficits in children with sickle cell disease. Pediatrics. 2005 Oct;116(4):943-9. doi: 10.1542/peds.2004-2582.
•   Burnham JM, Shults J, Semeao E, Foster B, Zemel BS, Stallings VA, Leonard MB
  Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res. 2004 Dec;19(12):1961-8. doi: 10.1359/JBMR.040908. Epub 2004 Sep 20.
•   Carpenter PA, Hoffmeister P, Chesnut CH 3rd, Storer B, Charuhas PM, Woolfrey AE, Sanders JE
  Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007 Jun;13(6):683-90. doi: 10.1016/j.bbmt.2007.02.001. Epub 2007 Apr 6.
•   Castillo H, Samson-Fang L; American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel
  Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol. 2009 Jan;51(1):17-29. doi: 10.1111/j.1469-8749.2008.03222.x.
•   Daniels MW, Wilson DM, Paguntalan HG, Hoffman AR, Bachrach LK
  Bone mineral density in pediatric transplant recipients. Transplantation. 2003 Aug 27;76(4):673-8. doi: 10.1097/01.TP.0000076627.70050.53.
•   Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C
  Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987;16(5):360-3. doi: 10.1007/BF00350961.
•   DiMeglio LA, Ford L, McClintock C, Peacock M
  Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone. 2004 Nov;35(5):1038-45. doi: 10.1016/j.bone.2004.07.003.
•   Gandrud LM, Cheung JC, Daniels MW, Bachrach LK
  Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol Metab. 2003 Jul-Aug;16(6):887-92. doi: 10.1515/jpem.2003.16.6.887.
•   Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R
  Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998 Oct 1;339(14):947-52. doi: 10.1056/NEJM199810013391402.
•   Glorieux FH
  Treatment of osteogenesis imperfecta: who, why, what? Horm Res. 2007;68 Suppl 5:8-11. doi: 10.1159/000110463. Epub 2007 Dec 10.
•   Gordon CM, Williams AL, Feldman HA, May J, Sinclair L, Vasquez A, Cox JE
  Treatment of hypovitaminosis D in infants and toddlers. J Clin Endocrinol Metab. 2008 Jul;93(7):2716-21. doi: 10.1210/jc.2007-2790. Epub 2008 Apr 15.
•   Grigg AP, Shuttleworth P, Reynolds J, Schwarer AP, Szer J, Bradstock K, Hui C, Herrmann R, Ebeling PR
  Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2006 Oct;91(10):3835-43. doi: 10.1210/jc.2006-0684. Epub 2006 Jul 11.
•   Grissom LE, Kecskemethy HH, Bachrach SJ, McKay C, Harcke HT
  Bone densitometry in pediatric patients treated with pamidronate. Pediatr Radiol. 2005 May;35(5):511-7. doi: 10.1007/s00247-004-1393-3. Epub 2005 Jan 18.
•   Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ
  Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr. 2002 Nov;141(5):644-51. doi: 10.1067/mpd.2002.128207.
•   Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society
  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6. Erratum In: J Clin Endocrinol Metab. 2011 Dec;96(12):3908.
•   Horlick M, Wang J, Pierson RN Jr, Thornton JC
  Prediction models for evaluation of total-body bone mass with dual-energy X-ray absorptiometry among children and adolescents. Pediatrics. 2004 Sep;114(3):e337-45. doi: 10.1542/peds.2004-0301.
•   Jackowski SA, Kontulainen SA, Cooper DM, Lanovaz JL, Baxter-Jones AD
  The timing of BMD and geometric adaptation at the proximal femur from childhood to early adulthood in males and females: a longitudinal study. J Bone Miner Res. 2011 Nov;26(11):2753-61. doi: 10.1002/jbmr.468.
•   Janssen van Doorn K, Neyns B, Van der Niepen P, Verbeelen D
  Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron. 2001 Dec;89(4):467-8. doi: 10.1159/000046123. No abstract available.
•   Janz KF, Letuchy EM, Eichenberger Gilmore JM, Burns TL, Torner JC, Willing MC, Levy SM
  Early physical activity provides sustained bone health benefits later in childhood. Med Sci Sports Exerc. 2010 Jun;42(6):1072-8. doi: 10.1249/MSS.0b013e3181c619b2.
•   Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Valimaki MJ
  Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab. 2005 Jul;90(7):3877-85. doi: 10.1210/jc.2004-2161. Epub 2005 Mar 29.
•   Kaste SC, Rai SN, Fleming K, McCammon EA, Tylavsky FA, Danish RK, Rose SR, Sitter CD, Pui CH, Hudson MM
  Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2006 Jan;46(1):77-87. doi: 10.1002/pbc.20553.
•   Kaste SC, Shidler TJ, Tong X, Srivastava DK, Rochester R, Hudson MM, Shearer PD, Hale GA
  Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004 Feb;33(4):435-41. doi: 10.1038/sj.bmt.1704360.
•   Land C, Rauch F, Travers R, Glorieux FH
  Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone. 2007 Mar;40(3):638-44. doi: 10.1016/j.bone.2006.10.010. Epub 2006 Nov 28.
•   Lin JH
  Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996 Feb;18(2):75-85. doi: 10.1016/8756-3282(95)00445-9.
•   Machado CE, Flombaum CD
  Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol. 1996 Mar;45(3):175-9.
•   Marshall WA, Tanner JM
  Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969 Jun;44(235):291-303. doi: 10.1136/adc.44.235.291. No abstract available.
•   Marshall WA, Tanner JM
  Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970 Feb;45(239):13-23. doi: 10.1136/adc.45.239.13.
•   Meyer U, Romann M, Zahner L, Schindler C, Puder JJ, Kraenzlin M, Rizzoli R, Kriemler S
  Effect of a general school-based physical activity intervention on bone mineral content and density: a cluster-randomized controlled trial. Bone. 2011 Apr 1;48(4):792-7. doi: 10.1016/j.bone.2010.11.018. Epub 2010 Dec 15.
•   Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M; Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society
  Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008 Aug;122(2):398-417. doi: 10.1542/peds.2007-1894.
•   Mostoufi-Moab S, Ginsberg JP, Bunin N, Zemel B, Shults J, Leonard MB
  Bone density and structure in long-term survivors of pediatric allogeneic hematopoietic stem cell transplantation. J Bone Miner Res. 2012 Apr;27(4):760-9. doi: 10.1002/jbmr.1499.
•   Nysom K, Holm K, Michaelsen KF, Hertz H, Jacobsen N, Muller J, Molgaard C
  Bone mass after allogeneic BMT for childhood leukaemia or lymphoma. Bone Marrow Transplant. 2000 Jan;25(2):191-6. doi: 10.1038/sj.bmt.1702131.
•   Papapoulos SE, Cremers SC
  Prolonged bisphosphonate release after treatment in children. N Engl J Med. 2007 Mar 8;356(10):1075-6. doi: 10.1056/NEJMc062792. No abstract available.
•   Perkins JL, Kunin-Batson AS, Youngren NM, Ness KK, Ulrich KJ, Hansen MJ, Petryk A, Steinberger J, Anderson FS, Baker KS
  Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer. 2007 Dec;49(7):958-63. doi: 10.1002/pbc.21207.
•   Petryk A, Bergemann TL, Polga KM, Ulrich KJ, Raatz SK, Brown DM, Robison LL, Baker KS
  Prospective study of changes in bone mineral density and turnover in children after hematopoietic cell transplantation. J Clin Endocrinol Metab. 2006 Mar;91(3):899-905. doi: 10.1210/jc.2005-1927. Epub 2005 Dec 13.
•   Petryk A, Polgreen LE, Zhang L, Hodges JS, Dengel DR, Hoffmeister PA, Steinberger J, Baker KS
  Bone mineral deficits in recipients of hematopoietic cell transplantation: the impact of young age at transplant. Bone Marrow Transplant. 2014 Feb;49(2):258-63. doi: 10.1038/bmt.2013.156. Epub 2013 Oct 14.
•   Plotkin H, Coughlin S, Kreikemeier R, Heldt K, Bruzoni M, Lerner G
  Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. Dev Med Child Neurol. 2006 Sep;48(9):709-12. doi: 10.1017/S0012162206001526. Erratum In: Dev Med Child Neurol. 2006 Dec;48(12):1024.
•   Polgreen LE, Rudser K, Deyo M, Smith A, Baker KS, Petryk A
  Changes in biomarkers of bone resorption over the first six months after pediatric hematopoietic cell transplantation. Pediatr Transplant. 2012 Dec;16(8):852-7. doi: 10.1111/j.1399-3046.2012.01780.x. Epub 2012 Aug 20.
•   Przkora R, Herndon DN, Sherrard DJ, Chinkes DL, Klein GL
  Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury. Bone. 2007 Aug;41(2):297-302. doi: 10.1016/j.bone.2007.04.195. Epub 2007 May 8.
•   Rauch F, Cornibert S, Cheung M, Glorieux FH
  Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone. 2007 Apr;40(4):821-7. doi: 10.1016/j.bone.2006.11.020. Epub 2007 Jan 12.
•   Rauch F, Glorieux FH
  Osteogenesis imperfecta. Lancet. 2004 Apr 24;363(9418):1377-85. doi: 10.1016/S0140-6736(04)16051-0.
•   Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH
  Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab. 2003 Mar;88(3):986-92. doi: 10.1210/jc.2002-021371.
•   Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA
  The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011 Jan;96(1):53-8. doi: 10.1210/jc.2010-2704. Epub 2010 Nov 29.
•   Ross PD, Davis JW, Epstein RS, Wasnich RD
  Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991 Jun 1;114(11):919-23. doi: 10.7326/0003-4819-114-11-919.
•   Speiser PW, Clarson CL, Eugster EA, Kemp SF, Radovick S, Rogol AD, Wilson TA; LWPES Pharmacy and Therapeutic Committee
  Bisphosphonate treatment of pediatric bone disease. Pediatr Endocrinol Rev. 2005 Dec;3(2):87-96.
•   Steelman J, Zeitler P
  Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr. 2003 Apr;142(4):417-23. doi: 10.1067/mpd.2003.137.
•   Tauchmanova L, Colao A, Lombardi G, Rotoli B, Selleri C
  Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2007 Dec;92(12):4536-45. doi: 10.1210/jc.2006-2870. Epub 2007 Oct 2.
•   Ward KA, Adams JE, Freemont TJ, Mughal MZ
  Can bisphosphonate treatment be stopped in a growing child with skeletal fragility? Osteoporos Int. 2007 Aug;18(8):1137-40. doi: 10.1007/s00198-007-0330-3. Epub 2007 Feb 6.
•   Ward LM, Denker AE, Porras A, Shugarts S, Kline W, Travers R, Mao C, Rauch F, Maes A, Larson P, Deutsch P, Glorieux FH
  Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab. 2005 Jul;90(7):4051-6. doi: 10.1210/jc.2004-2054. Epub 2005 Apr 12.
•   Whyte MP, McAlister WH, Novack DV, Clements KL, Schoenecker PL, Wenkert D
  Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res. 2008 Oct;23(10):1698-707. doi: 10.1359/jbmr.080511.
•   Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S
  Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003 Jul 31;349(5):457-63. doi: 10.1056/NEJMoa023110. No abstract available.
•   Zacharin M, Bateman J
  Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab. 2002 Feb;15(2):163-74. doi: 10.1515/jpem.2002.15.2.163.

Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation

Details for clinical trial NCT02074631